MBS-303 - Drug Targets, Indications, Patents - Synapse - Patsnap

mbs303MBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) confuration to kill malnant B cells. This dose-escalation phase Ⅰ trial evaluated the safetyMBS303 | LOGIN MBS303 | DAFTAR MBS303 | LINK MBS303 | SITUS MBS303 | LINK MBS 303 | DAFTAR MBS